Login / Signup

Risk factors of proteinuria and potentially protective effect of renin-angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib.

Hiroaki IkesueKenta YamaokaAyako MatsumotoMasaki HirabatakeNobuyuki MuroiToshinari YamasakiMutsushi KawakitaTohru Hashida
Published in: Cancer chemotherapy and pharmacology (2022)
In patients with RCC receiving axitinib, pre-existing proteinuria and non-RAS inhibitor use were significantly associated with grade ≥ 2 proteinuria development. Our preliminary data should be confirmed by further studies.
Keyphrases
  • renal cell carcinoma
  • risk factors
  • metastatic renal cell carcinoma
  • electronic health record
  • big data
  • case control
  • artificial intelligence
  • deep learning